PETER HOTEZ to Antibodies, Viral
This is a "connection" page, showing publications PETER HOTEZ has written about Antibodies, Viral.
Connection Strength
0.985
-
Optimizing immunogenicity and product presentation of a SARS-CoV-2 subunit vaccine composition: effects of delivery route, heterologous regimens with self-amplifying RNA vaccines, and lyophilization. Front Immunol. 2024; 15:1480976.
Score: 0.145
-
SARS-CoV-2 variants offer a second chance to fix vaccine inequities. Nat Rev Microbiol. 2023 03; 21(3):127-128.
Score: 0.128
-
From concept to delivery: a yeast-expressed recombinant protein-based COVID-19 vaccine technology suitable for global access. Expert Rev Vaccines. 2023 Jan-Dec; 22(1):495-500.
Score: 0.127
-
COVID-19 vaccine decisions: considering the choices and opportunities. Microbes Infect. 2021 May-Jun; 23(4-5):104811.
Score: 0.112
-
Developing a low-cost and accessible COVID-19 vaccine for global health. PLoS Negl Trop Dis. 2020 07; 14(7):e0008548.
Score: 0.107
-
COVID-19 vaccine design: the Janus face of immune enhancement. Nat Rev Immunol. 2020 06; 20(6):347-348.
Score: 0.105
-
Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome. Expert Rev Vaccines. 2012 Dec; 11(12):1405-13.
Score: 0.063
-
Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concern. Vaccine. 2022 06 09; 40(26):3655-3663.
Score: 0.030
-
An aluminum hydroxide:CpG adjuvant enhances protection elicited by a SARS-CoV-2 receptor binding domain vaccine in aged mice. Sci Transl Med. 2022 Jan 26; 14(629):eabj5305.
Score: 0.030
-
A yeast expressed RBD-based SARS-CoV-2 vaccine formulated with 3M-052-alum adjuvant promotes protective efficacy in non-human primates. Sci Immunol. 2021 07 15; 6(61).
Score: 0.029
-
SARS-CoV-2 RBD219-N1C1: A yeast-expressed SARS-CoV-2 recombinant receptor-binding domain candidate vaccine stimulates virus neutralizing antibodies and T-cell immunity in mice. Hum Vaccin Immunother. 2021 08 03; 17(8):2356-2366.
Score: 0.028
-
SARS-CoV-2 seroprevalence worldwide: a systematic review and meta-analysis. Clin Microbiol Infect. 2021 Mar; 27(3):331-340.
Score: 0.027
-
Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with aluminum hydroxide induces protective immunity and reduces immune enhancement. Vaccine. 2020 11 03; 38(47):7533-7541.
Score: 0.027
-
Coronavirus vaccine-associated lung immunopathology-what is the significance? Microbes Infect. 2020 10; 22(9):403-404.
Score: 0.027